Chaisungnern Kanchaporn, Rattananupong Thanapoom, Klinhom Rossukon, Nanta Srisuphak, Banchuen Kamonwan, Itharat Arunporn, Kuropakornpong Pranporn, Supasiri Thanan, Nootim Preecha, Jiamjarasrangsi Wiroj
Health Research and Management Program, Department of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Institute of Thai Traditional Medicine, Department of Thai Traditional and Alternative Medicine, Ministry of Public Health, Thailand.
Complement Ther Med. 2025 Aug;91:103185. doi: 10.1016/j.ctim.2025.103185. Epub 2025 May 5.
Hibiscus sabdariffa L. (HS) has been investigated as an alternative treatment for metabolic syndrome (MetS), as it affects all MetS components with low side effects simultaneously; however, clinical evidence regarding its efficacy compared with placebo is inconsistent. This study assessed how the aqueous calyx extract of HS influences insulin resistance and MetS parameters and examined the safety effects on liver, kidney, and hematological indexes in participants with abdominal obesity and mild MetS symptoms.
In this double-blind, randomized, placebo-controlled trial, 108 participants with MetS were randomly assigned to take 1000-mg HS (45.04 mg/day in total polyphenols) or placebo daily for 12 weeks. Insulin resistance (HOMA-IR), glycemic markers, body mass index (BMI), waist circumference (WC), lipid profiles, and blood pressure were assessed at baseline, 6 weeks, and 12 weeks. Additionally, liver and kidney function indicators along with hematological parameters were evaluated.
Compared with placebo, HS did not significantly affect HOMA-IR, glycemic markers, BMI, WC, lipid profile, or blood pressure. Although HS did not significantly alter the lipid profile overall, serum low-density lipoprotein (LDL) levels decreased significantly at 12 weeks compared with baseline (- 7.98 mg/dL, [95 % CI, - 14.80, - 1.15]). Additionally, HS did not cause significant liver or kidney function or hematological changes compared with placebo.
Taking 1000-mg HS daily for 12 weeks seems to be safe. Placebo and HS groups showed good clinical results, and the extract was not associated with improved metabolic parameters in individuals with abdominal obesity and mild MetS symptoms, with the exception of lower serum LDL.
玫瑰茄（HS）已被研究作为代谢综合征（MetS）的一种替代治疗方法，因为它能同时影响所有MetS组分且副作用小；然而，与安慰剂相比其疗效的临床证据并不一致。本研究评估了HS水萼提取物如何影响胰岛素抵抗和MetS参数，并检查了其对腹部肥胖和轻度MetS症状参与者的肝脏、肾脏和血液学指标的安全性影响。
在这项双盲、随机、安慰剂对照试验中，108名MetS参与者被随机分配，每天服用1000毫克HS（总多酚含量为45.04毫克/天）或安慰剂，持续12周。在基线、6周和12周时评估胰岛素抵抗（HOMA-IR）、血糖指标、体重指数（BMI）、腰围（WC）、血脂谱和血压。此外，还评估了肝功能和肾功能指标以及血液学参数。
与安慰剂相比，HS对HOMA-IR、血糖指标BMI、WC、血脂谱或血压没有显著影响。虽然HS总体上没有显著改变血脂谱，但与基线相比，血清低密度脂蛋白（LDL）水平在12周时显著下降（-7.98毫克/分升，[95%置信区间，-14.80，-1.15]）。此外，与安慰剂相比，HS没有引起显著的肝功能、肾功能或血液学变化。
每天服用1000毫克HS，持续12周似乎是安全的。安慰剂组和HS组均显示出良好的临床结果，除血清LDL降低外，该提取物与腹部肥胖和轻度MetS症状个体的代谢参数改善无关。
